1. 7-Amine-spiro[chromeno[4,3-b]quinoline-6,1'-cycloalkanes]: Synthesis and cholinesterase inhibitory activity of structurally modified tacrines.
- Author
-
Silva LB, Nogara PA, Halmenschelager PT, Alvim JC, Silva FD, Feitosa SC, Rocha JBT, Martins MAP, Zanatta N, and Bonacorso HG
- Subjects
- Animals, Cholinesterase Inhibitors chemical synthesis, Cholinesterase Inhibitors chemistry, Cycloparaffins chemical synthesis, Cycloparaffins chemistry, Dose-Response Relationship, Drug, Electrophorus, Horses, Molecular Docking Simulation, Molecular Structure, Quinolines chemical synthesis, Quinolines chemistry, Structure-Activity Relationship, Cholinesterase Inhibitors pharmacology, Cholinesterases metabolism, Cycloparaffins pharmacology, Quinolines pharmacology
- Abstract
Five new examples of 9,10-chloro(bromo)-7-amine-spiro[chromeno[4,3-b]quinoline-6,1'-cycloalkanes] - in which cycloalkanes = cyclopentane, cyclohexane, and cycloheptane - were synthesized at yields of 42-56%, using a sequential one-pot two-step cyclocondensation reaction of three different scaffolds of 2-aminobenzonitriles and the respective spiro[chroman-2,1'-cycloalkan]-4-ones, and using AlCl
3 as the catalyst in a solvent-free method. Subsequently, the five new spirochromeno-quinolines and nine quinolines previously published by us (14 modified tacrine scaffolds) were subjected to AChE and BChE inhibitory activity evaluation. The molecule containing a spirocyclopentane derivative had the highest AChE and BChE inhibitory activity (IC50 = 3.60 and 4.40 μM, respectively), and in general, the non-halogenated compounds were better inhibitors of AChE and BChE than the halogenated molecules. However, the inhibitory potency of compounds 3a-n was weaker than that of tacrine. By molecular docking simulations, it was found that the size of the spirocarbocyclic moieties is inversely proportional to the inhibitory activity of the cholinesterases, probably because an increase in the size of the spirocyclic component sterically hindered the interaction of tacrine derivatives with the active site of tested cholinesterases. The findings obtained here may help in the design and development of new anticholinesterase drugs., (Copyright © 2021 Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF